Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX) ...

The FDA approves Imaavy, a groundbreaking treatment for generalized myasthenia gravis (gMG), offering symptom relief and reduced autoantibody levels in adults and children over 12.

FDA Approves Johnson & Johnson’s IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families ...

Inebilizumab treatment improves function and reduces disease severity in patients with generalized myasthenia gravis (MG), a study found.

The investigational FcRn blocker is being developed for the treatment of myasthenia gravis in patients with antibodies against AChR, MuSK or LRP4. The company recently announced positive results from ...

To review: Myasthenia gravis is an autoimmune condition that affects the neuromuscular junction between the nerve and the muscle often referred to as the neuromuscular end plate.

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

The FDA approved Soliris for children aged 6 and older with generalized myasthenia gravis (gMG), offering new hope for managing this autoimmune neuromuscular disorder.

FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children Provided by GlobeNewswire Mar 10, 2025 1:09pm ...